New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates - Wikidata - wikimedia - TriplyDB

New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates

New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates

http://www.wikidata.org/entity/Q42693542

about

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe.Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes

P2860

Q30275728-A990FA1C-6AAE-409A-9C8D-299E43C01EC8 Q33745972-44AE78AD-396F-436D-8054-72CB20ED9383 Q36396241-BD1494C8-600E-4BD3-8D3E-3A1552CE44FE Q37287787-309B4527-7F2F-4F46-BF0C-0C9A6683BF70 Q37434301-C990881A-8C55-4A23-BEFF-C95B3D9FEA8A Q38213320-B25D125C-7D63-44C4-AC83-C1E80B081FA1 Q38865905-AB979857-E471-41CE-8813-604A465A9E7D Q49792011-EFBD2552-22F8-4CC5-91E5-E330FBB944AC Q57152709-0017D569-F9DC-4C0A-B11E-A94EF37F3B60

P2860

New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates

http://www.wikidata.org/entity/Q42693542

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

New susceptibility breakpoints ...... acterium tuberculosis isolates

@en

New susceptibility breakpoints ...... acterium tuberculosis isolates

@nl

type

label

New susceptibility breakpoints ...... acterium tuberculosis isolates

@en

New susceptibility breakpoints ...... acterium tuberculosis isolates

@nl

prefLabel

New susceptibility breakpoints ...... acterium tuberculosis isolates

@en

New susceptibility breakpoints ...... acterium tuberculosis isolates

@nl

P1433

Q42693542-3900E3BB-A36E-4DAC-AB47-B4BF0D099014

P1476

Q42693542-3CF76F83-A710-4C24-8013-85F894BB2526

P2093

Q42693542-57057C02-2DB6-4232-941E-4C56A4E10DA6

P2860

Q42693542-3EE66E79-3856-4BA4-AED4-FDA2BF727EFD

Q42693542-AB51D42C-51F4-4ADB-BAD7-B9A1B163963D

Q42693542-B0652EEF-A9CB-4B82-BAD0-6B9A3953CA84

Q42693542-C0A9F0ED-91B5-4B35-A8E6-9746136CA017

Q42693542-C4A070B3-F737-49B1-BFEC-197DEFA34296

P304

Q42693542-A5ADA27F-B79B-4DDF-99CB-D2372401656C

P31

Q42693542-57DF1568-431B-4523-9D79-E7BECDDAFE33

P356

Q42693542-01385EC6-3046-4C0F-8E3B-B6630DEEBF85

P407

Q42693542-758845B7-3D63-46B1-8CF7-456E56A03354

P433

Q42693542-47E6E15A-9978-412D-ACB0-3D2FD1E39737

P478

Q42693542-D27DD31A-4502-4250-BAC8-6BE034463F60

P50

Q42693542-C73F0654-4DD3-40F7-B3FB-22A407E4BA23

Q42693542-F13E96AC-E160-4CF9-B1C9-B8317D9A5765

P577

Q42693542-81899228-E8B1-4311-8FA4-CAF7E3043E9F

P5875

Q42693542-271FB100-6C65-42A2-A9D6-54B3A5342A58

P698

Q42693542-B50157D4-8206-43F4-800B-73EA39E8B73F

P921

Q42693542-FDDF4629-C058-4838-AA63-810516766C4A

P932

Q42693542-23AF3DF6-A767-43C5-9C68-4FD06F74459E

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

New susceptibility breakpoints ...... acterium tuberculosis isolates

@en

P2093

Jotam Pasipanodya

http://www.w3.org/2001/XMLSchema#string

P2860

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis

Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.

New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.

P304

5428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00976-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Shashikant Srivastava

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230843403

http://www.w3.org/2001/XMLSchema#string

P698

22972799

http://www.w3.org/2001/XMLSchema#string

P921

Mycobacterium tuberculosis

P932

3457406

http://www.w3.org/2001/XMLSchema#string